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1 Abstract
The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic1
heterogeneity. The current approach to address resistance typically involves initiating a new treatment after2
clinical/radiographic disease progression, ultimately resulting in futility in most patients. Towards a poten-3
tial alternative solution, we developed a novel computational framework that uses human cancer profiling4
data to systematically identify dynamic, pre-emptive, and sometimes non-intuitive treatment strategies that5
can better control tumors in real-time. By studying lung adenocarcinoma clinical specimens and preclinical6
models, our computational analyses revealed that the best anti-cancer strategies addressed existing resistant7
subpopulations as they emerged dynamically during treatment. In some cases, the best computed treatment8
strategy used unconventional therapy switching while the bulk tumor was responding, a prediction we con-9
firmed in vitro. The new framework presented here could guide the principled implementation of dynamic10
molecular monitoring and treatment strategies to improve cancer control.11
2 Introduction12
Targeted cancer therapies are eﬀective for the treatment of certain oncogene-driven solid tumors, including13
non-small cell lung cancers (NSCLCs) with activating genetic alterations in EGFR (epidermal growth factor14
receptor), ALK (anaplastic lymphoma kinase), BRAF, and ROS1 kinases [1, 2, 3]. However, inevitably resis-15
tance to current targeted therapies emerges, typically within months of initiating treatment and remains an16
obstacle to long-term patient survival [1, 2, 3, 4]. The presence and evolution of tumor genetic heterogeneity17
potentially underlies resistance and also limits the response to successive therapeutic regimens that are used18
clinically in an attempt to overcome resistance in the tumor after it has emerged [4, 5, 6, 7]. Indeed, while19
a targeted therapy may be eﬀective in suppressing one genomic subclone within the tumor, other clones20
may be less sensitive to the eﬀects of the drug. Thus, through selective pressures, resistant populations can21
emerge and promote tumor progression. Moreover, the current paradigm of solid tumor treatment is largely22
based on designing fixed (static) treatment regimens that are deployed sequentially as either initial therapy23
or after the clear emergence of drug-resistant disease, detected by clinical and radiographic measures of24
tumor progression. In contrast, designing dynamic treatment strategies that switch between targeted agents25
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(or combinations thereof) in real time in order to suppress the outgrowth of rare or emergent drug-resistant26
subclones may be a more eﬀective strategy to continually suppress tumor growth and extend the duration of27
clinical response. Thus, there is a need to identify principled approaches for the predictive design of eﬀective28
combination (poly)therapy strategies to pre-empt the growth of multiple tumor subclones actively during29
treatment.30
Mathematical modeling, analysis and computational simulations of tumor growth, heterogeneity and31
inhibition by various therapeutic modalities has long been employed as a method to provide insight into32
evolutionary outcomes and eﬀective treatment strategies. Such modeling may include the use of stochastic33
[8, 9, 10] or deterministic diﬀerential equation implementations [11, 12] to propose static or sequential34
treatment strategies that delay resistance in various cancer models. Recent studies by Zhao et al. [13, 14]35
incorporate the use of mathematical optimization, a fundamental subject in engineering design to predict36
static combination therapies that eﬀectively address heterogeneity in a lymphoma model. Complementary37
engineering techniques from optimal control theory provide an additional theoretical framework to design38
dynamic drug scheduling regimens in the context of dynamical systems models of cancer heterogeneity and39
evolution. The application of optimal control theory to treatment design has a history dating back to the40
1970s [15, 16] with more recent examples including that of scheduling angiogenic and chemotherapeutic41
agents [17] or immuno- and chemotherapy combinations [18]. While mathematical modeling and engineering42
methods have been used extensively to inform treatment strategy design, a significant drawback to prior work43
in the field is that the underlying computational framework(s) have not conjointly accomplished the following44
important aims: (1) allowing for the systematic principled design of dynamic treatment strategies using45
experimentally identified models of tumor dynamic behaviors; and (2) developing quantitative methods that46
allow for the exploration of the robustness of predicted treatment strategies with respect to multiple common47
challenges in real-world patients, such as tumor heterogeneity and fluctuations in drug concentrations.48
Here, we present a novel approach that combines a mathematical model of the evolution of tumor cell49
populations with parameters identified from our experimental data and an engineering framework for the50
systematic design of polytherapy scheduling directed at the following unresolved issues in the field: (1) how51
tumor genetic composition and drug dose constraints aﬀect the long term eﬃcacy of combination strategies,52
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(2) how optimal scheduling of combination small molecule inhibitors can help to overcome heterogeneity, ge-53
nomic evolution and drug dose fluctuations, and (3) how serial tumor biopsy or blood-based tumor profiling54
scheduling in patients can be timed appropriately. To tackle these questions, we developed an integrated55
experimental and computational framework that solves for candidate combination treatment strategies and56
their scheduling given an initial polyclonal tumor and allows the exploration of treatment design trade oﬀs57
such as dosage constraints and robustness to small fluctuations in drug concentrations. This methodology58
is rooted in optimal control theory and incorporates an experimentally derived mathematical model of evo-59
lutionary dynamics of cancer growth, mutation and small molecule inhibitor pharmacodynamics to solve60
for optimal drug scheduling strategies that address tumor heterogeneity and constrain drug-resistant tumor61
evolution. Our key new insights include (1) heterogeneous tumor cell populations are better controlled with62
switching strategies; indeed, static two-drug strategies are unable to eﬀectively control all tumor subpop-63
ulations in our study; (2) constant combination drug strategies are less robust to perturbations in drug64
concentrations for heterogeneous tumor cell populations, and hence more likely to lead to tumor progression;65
(3) countering the outgrowth of subclonal tumor populations by switching polytherapies even during a bulk66
tumor response can oﬀer better tumor cell population control, oﬀering a non-intuitive clinical strategy that67
pro-actively addresses molecular progression before evidence of clinical or radiographic progression appears.68
3 Results69
3.1 The presence and evolution of intratumoral genetic heterogeneity in a pa-70
tient with EGFR-mutant lung adenocarcinoma71
To explore the utility of our approach, we focused on EGFR-mutant lung adenocarcinoma. Many mechanisms72
of resistance to EGFR-targeted therapies in lung adenocarcinoma are well characterized [19]. Furthermore,73
tumor heterogeneity and multiple resistance mechanisms arising in a single patient can occur [2, 19]. Thus,74
overcoming polygenic resistance is of paramount importance in this disease and will likely require a non-75
standard approach. To illustrate this point, we investigated the molecular basis of targeted therapy resistance76
in a 41-year old male never-smoker with advanced EGFR-mutant (L858R) lung adenocarcinoma. This pa-77
tient responded to first-line treatment with erlotinib but progressed on this therapy within only four months78
after initial treatment, instead of the typical 9-12 month progression free survival observed in EGFR-mutant79
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lung adenocarcinoma patients. We reasoned that genomic analysis of this patient’s outlier clinical pheno-80
type could reveal the molecular pathogenesis of suboptimal erlotinib response. Using a custom-capture assay81
[20, 21], we deeply sequenced the coding exons and selected introns of 389 cancer-relevant genes in both the82
pre-treatment and the erlotinib-resistant tumor specimen and matched normal blood to identify somatic83
alterations that could mediate resistance (Materials and Methods). Exome sequencing of the pre-treatment84
specimen confirmed the presence of the EGFRL858R mutant allele that was identified through prior clinical85
PCR-based sequencing of this EGFRL858R specimen (data not shown), and additionally revealed mutant86
allele-specific focal amplification of the EGFR coding locus that resulted in a high allelic frequency (95%87
variant frequency) (Fig. 1B-C). We discovered a rare concurrent subclone in the treatment-naïve tumor88
with a BRAFV600E mutation (6% variant frequency; Fig. 1B). This observation is consistent with a recent89
report of a BRAFV600E mutation in an erlotinib-resistant lung adenocarcinoma specimen [22] and recent data90
indicating that EGFR-mutant lung adenocarcinoma cells can often develop EGFR TKI resistance through91
RAF-MEK-ERK pathway activation [23]. The frequency of the subclonal BRAFV600E mutation increased92
approximately 10-fold upon acquired erlotinib resistance, from 6% to 60% in the primary and recurrent93
tumor, respectively (Figure 1C). This increase in the BRAFV600E allelic fraction was likely due to the ex-94
pansion of the BRAFV600E subclone, given that we found no evidence that this increased frequency occurred95
as a result of focal BRAF amplification in the resistant tumor (Figure 1C). Beyond the outgrowth of mutant96
BRAF, we identified two additional genetic alterations in the resistant tumor that could contribute to EGFR97
TKI resistance: focal amplification of 7q31.2 encoding MET in the resistant tumor cells, a low frequency98
EGFRT790M mutation (14% variant frequency) (Fig. 1B-C). All candidate somatic mutations and focal99
copy number amplifications conferring resistance to erlotinib therapy (in EGFR, BRAF, and MET) were100
confirmed by independent, validated DNA sequencing and FISH assays (data not shown). Thus, erlotinib101
therapy acted as a selective pressure for the evolution of multiple concurrent clonal and subclonal genetic102
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3.2 Analysis of clonal concurrence and resistance106
While BRAFV600E, MET activation, and EGFRT790M can individually promote EGFR TKI resistance [22, 24,107
25], the therapeutic impact of the concurrence of these alterations we uncovered has not been characterized.108
Therefore, we studied the eﬀects of BRAFV600E, MET activation, and EGFRT790M, alone or in combination,109
on growth and therapeutic response in human EGFR-mutant lung adenocarcinoma cellular models. First,110
we found that expression of V600E but not wild-type (WT) BRAF promoted resistance to erlotinib in 11-18111
cells that endogenously express EGFRL858R (Fig. S1). This erlotinib resistance in BRAFV600E-expressing112
EGFR-mutant 11-18 cells was overcome by concurrent treatment with erlotinib and selective inhibitors of113
either BRAF or MEK (vemurafenib [26] and trametinib [27] respectively (Fig. S2, S3). We next used the114
11-18 system to test the eﬀects of MET activation by hepatocyte growth factor (HGF), which phenocopies115
the eﬀects of MET amplification in EGFR TKI resistance[25, 28] on therapeutic sensitivity. We found that116
MET activation not only promoted erlotinib resistance in parental 11-18 cells but also enhanced the eﬀects117
of BRAFV600E expression on erlotinib resistance in these cells (Fig. S1). This resistance induced by MET118
activation in 11-18 parental and BRAFV600E-expressing cells was accompanied by increased phosphorylation119
of MEK, ERK, and AKT (Fig. S3). Treatment with the MEK inhibitor trametinib, but not the BRAF120
inhibitor vemurafenib or the MET inhibitor crizotinib, overcame erlotinib resistance and inhibited phospho-121
ERK in MET-activated BRAFV600E-expressing 11-18 cells (Fig. S3), providing a rationale for polytherapy122
against EGFR and MEK in EGFR-mutant tumors with activating co-alterations in MET and BRAF.123
Given that we found a rare EGFRT790M subclone in the polyclonal resistant tumor, we next explored124
whether BRAFV600E expression could promote resistance to EGFR TKI treatment in H1975 human lung125
adenocarcinoma cells that endogenously express EGFRT790M and EGFRL858R. We observed that BRAFV600E126
modestly decreased sensitivity to afatinib, an approved irreversible EGFR kinase inhibitor eﬀective against127
EGFRT790M [29], and that this eﬀect of BRAFV600E on afatinib sensitivity was blunted by vemurafenib (Fig.128
S4). Together, our data indicate that erlotinib therapy induced the evolution of multiple concurrent events129
that re-shaped the polyclonal tumor genetic landscape during the onset of resistance; resistance could be130
overcome by polytherapy against both EGFR and MAPK signaling in preclinical models.131
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3.3 Polytherapy Provides Temporary Response in Heterogeneous or MET Ac-132
tivated Tumors133
While we conducted a finite set of experiments to test various rational drug combinations that could address134
the heterogeneous basis of resistance in this patient’s disease, this approach is not easily scaled; further, it135
is not readily feasible to explore all possible drug combinations and drug doses over a continuous range or136
anticipate the eﬀects of the myriad of possible tumor subcompositions on tumor control under treatment137
using cell-based assays alone. Therefore, we sought to provide a more general and scalable framework for138
understanding the impact of each genetically-informed targeted therapy strategy on the temporal evolution139
of the multiple concurrent EGFR-mutant tumor cell subclones present in this patient, as a potentially more140
generalizable platform. We developed an ordinary diﬀerential equation (ODE) model of tumor growth,141
mutation and selection by small molecule inhibitors with parameters identified from experimental data (Fig.142
2A-B and Equation S1) and interrogated it to uncover the limitations of the targeted treatments in the context143
of tumor heterogeneity and evolution. We first confirmed that our model was able to capture the essential144
tumor population dynamics by showing a qualitative equivalence between the patient’s clinical course and145
our model simulation of similar tumor subpopulations consisting of 94 % EGFRL858R, 6% BRAFV600E and146
assuming the existence of a very low initial frequency of 0.01%MET amplification of EGFRL858R, BRAFV600E147
and EGFRT790M in the presence of 1 µM erlotinib (Fig. 3A-B).148
To systematically explore the utility of many diﬀerent drug combination regimens to overcome polygenic149
resistance, we used our computational model to calculate the eﬃcacy of clinically relevant doses of erlotinib150
and afatinib in combination with either crizotinib, trametinib or vemurafenib on the growth of parental151
11-18 and H1975 cells EGFR mutant cell lines. We found that most polytherapies could address only certain152
subpopulations (Fig. 4A). For example, the afatnib/trametinib combination elicited a complete response for153
a representative heterogeneous MET- tumor cell population comprised of (89% EGFRL858R, 10% EGFRL858R154
BRAFV600E, 1% EGFRL858R, T790M) compared to rapid progression for its MET activated analog (Fig. 4C).155
Moreover, we computed the concentrations of erlotinib or afatinib in combination that could guarantee a156
progression-free response for both MET activated or MET neutral tumor cell populations (SI, Mathematical157
Methods) and found that in many cases, the concentrations were considerably higher than clinically feasible158
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(due to either known pharmacokinetic limitations or dose limiting toxicities) (Fig. 4B).159
To better understand the eﬃcacy of the combination therapy over time, we sought to classify which160
initial tumor cell subpopulations could eventually lead to therapeutic failure when treated with diﬀerent161
concentrations of EGFR TKIs in combination with crizotinib, trametinib or vemurafenib. We defined the162
evolutionary stability of a subpopulation as the worst-case evolutionary outcome, in each case where the163
particular subpopulation is present upon treatment initiation. More precisely, the evolutionary stability is164
the maximum eigenvalue of each evolutionary branch downstream of the subclone (SI, Section 3.2). This165
approach provides an assessment of which subclones present in the initial tumor cell population are likely166
to lead to overall progression (a positive evolutionary stability) versus those that lead to response (a neg-167
ative evolutionary stability) when treated with a particular combination therapy. Our analysis confirms168
that progression-free response on combination therapies is sensitive to both EGFR TKI concentration and169
dependent on whether pre-existent subpopulations are eﬀectively targeted at these concentrations (Fig. 4D170
and Fig. S5-S7). Overall, this analysis revealed that combinations of two signal transduction inhibitors had171
limited eﬀectiveness in durably controlling resistance over a longer time horizon.172
3.4 Engineering Drug Scheduling to Control Tumor Evolution173
We next explored how the rational design of combination drug scheduling strategies could address this issue.174
Experimental studies have recently proposed drug pulsing [30] or drug switching [10] as a strategy to delay175
the growth of certain cancers. To this end, we proposed a novel methodology rooted in engineering principles176
to design drug scheduling strategies that best control the growth and evolution of tumor cell populations.177
In particular, we apply concepts from optimal and receding horizon control theory to our experimentally178
integrated model of lung adenocarcinoma evolution to compute treatment strategies that minimize tumor179
cell populations over time. Our algorithm allows for the specification of treatment design constraints such as180
maximum dose, the time horizon over which the treatment strategy is applied and the switching horizon, that181
is the minimum time over which one particular treatment can be applied. This algorithm can be extended182
to include other drug related characteristics and treatment design constraints. In addition, the framework183
allows for the analysis of tradeoﬀs between these aspects of the design space as well as others, such as how184
robust the predicted treatment strategies are with respect to uncertainties in the model or perturbations in185
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drug dosages.186
For a predetermined time and minimum switching horizon, we define an optimal control problem (SI,187
Algorithm 1) and solve for the drug combination that best minimizes the existing tumor cell subpopulations188
for every receding switching horizon. Given that any one polytherapy is unlikely to be simultaneously eﬀective189
against all subpopulations, the resulting optimal strategy, which maximizes the response of the tumor cells190
present at every time horizon (SI, Mathematical Methods), is potentially one that switches between drug191
combinations, at defined time points during the treatment course.192
As proof-of-principle, we determined which drug scheduling regimens could maximally reduce diﬀerent193
initial tumor cell populations by solving our control problem for diﬀerent allowable switching horizons over a194
thirty day period (Fig. 5). The afatinib/trametinib combination was the optimal constant strategy for tumor195
cell populations harboring the EGFRL858R,T790M mutation, and although this strategy invoked progression196
free response in HGF- tumor cell populations, most L858R HGF+ tumor cell populations progressed on197
the therapy over thirty days (Fig. 5A vs 5C and Fig. S6AB). For the HGF- tumor population comprised198
of 89% EGFRL858R, 10% EGFRL858RBRAFV600E and 1% EGFRL858R,T790M, the optimal constant strategy199
provided overall response leaving a dominant EGFRL858RBRAFV600E tumor subpopulation present whereas200
the optimal ten day switching strategy provided an enhanced response over the constant strategy by alter-201
nately targeting EGFRL858R and EGFRL858R, T790M tumor cell subpopulations (Fig. 5B). In the case of the202
HGF treated tumor cell distribution consisting of 90% EGFRL858R and 10% EGFRL858R,T790M, a constant203
combination of afatinib/trametinib was eﬀective against the EGFRL858R,T790M, HGF+ subpopulation de-204
spite overall progression due to the outgrowth of the EGFRL858R, HGF+ tumor cell population, whereas205
a five day switching regimen between afatinib/trametinib and erlotinib/crizotinib combinations alternately206
targeted the HGF+ EGFRL858R,T790M and the EGFRL858R subpopulations (Fig. 5B and Fig. 3A) leading207
to overall response.208
More generally, the optimal constant strategies determined by our algorithm are combinations that best209
minimize existing tumor cell subpopulations at every switching horizon. In particular, a greater reduction in210
tumor cells can be achieved by switching between therapies that alternately target diﬀerent subpopulations,211
even while there is overall response in the tumor (Fig. 5A). This finding suggests a non-intuitive approach to212
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the clinical management of solid tumors that would represent a departure from the current standard clinical213
practice. Our model suggests an advantage to switching treatments pro-actively even during a bulk tumor214
response, while the current paradigm in the field is to switch from the initial treatment to a new drug(s)215
only after there is clear evidence of radiographic or clinical progression on the initial treatment.216
To understand the potential benefits of switching strategies in tumors with diﬀerent initial genetic hetero-217
geneity, we computed the optimal switching strategies for a subset of tumor cell distributions and compared218
them to their corresponding computed optimal constant strategies. We found that the larger the number219
of subclones present in the initial tumor, the more beneficial even a small number of switches could be220
for overall tumor cell population control (Fig. 6A and Fig. S8A). For a highly heterogeneous tumor cell221
population comprised of HGF treated 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R,T790M222
mutations, the predicted fifteen day switching therapy (afatinib/trametib followed by erlotinib/crizotinib)223
provides an immediate benefit versus the predicted constant treatment strategy (afatinib/trametinib), yield-224
ing a 10-fold decrease in final tumor population. By contrast, for a more homogeneous tumor consisting225
of 90% EGFRL858R, 10% EGFRL858R,T790M, the optimal predicted 30, 15 and 10 day switching strategies226
are indistinguishable from the constant therapy strategy for population control. Our predictions indicate227
that a similar 10-fold reduction in final population (similar to that achieved in the heterogeneous tumor228
instance analyzed above) is achieved only with a more rapid, five day switching strategy for this more ho-229
mogeneous tumor population (afatinib/trametinib, then alternating between erlotinib/trametinib and afa-230
tinib/vemurafenib). These findings emphasize our results that while polytherapy may a provide response231
in some subsets of tumor cell populations, it provides only a temporary or no response in heterogeneous or232
MET activated tumors; in these cases, even minimal therapy switching can provide an immediate and more233
substantial benefit for overall tumor population control.234
3.5 Robustness Analysis of Switching Strategies235
Motivated by studies indicating that tissue to plasma ratios for certain drugs such as erlotinib can be low [31],236
we sought to computationally explore how dose reductions of TKI combinations could aﬀect the evolution of237
tumor cell populations. This is a particularly relevant clinical issue, as many drugs when used in combination238
often require a reduction in the recommended monotherapy dose due to toxicity of the dual drug therapy239
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in patients. To examine this question, we simulated the optimal switching strategies corresponding to 30,240
15, 10, 5 and 1 day switching horizons subject to EGFR TKI dose reductions for a set of initial tumor241
cell populations and studied the eﬀects on the final and average tumor populations over the course of the242
treatment (SI, Mathematical Methods).243
For a tumor with a smaller number of initial subclones, such as one comprised of 90% EGFRL858R244
and 10% EGFRL858R,T790M, all switching strategies induced a response for EGFR TKI dose reductions of245
up to 50% (Fig. 6A). In contrast, with the more complex HGF treated tumor cell population comprised246
of 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R,T790M, only combination strategies with247
switching horizons of 10 day or shorter induced a response (Fig. 6B). Notably, we observed that the shorter248
the switching horizon, the higher dose reduction that could be supported while still maintaining a progression249
free response (Fig. 6B and Fig. S8B). We observed this phenomenon more generally when we simulated250
diﬀerent tumor cell initial distributions (Fig. 6C). Thus, we find that the greater number of subclones251
present in the initial tumor, the greater the benefit there is in increasing switching frequency in terms of the252
achieving robustness to perturbations in EGFR TKI drug concentration.253
3.6 Switching Strategies Control or Delay Progression in Vitro254
Motivated by the results of our treatment strategy algorithm, we tested drug scheduling strategies on select255
tumor subpopulations in an in vitro model of EGFR mutant lung adenocarcinoma. Specifically, we syn-256
thesized the optimal treatment strategy for a heterogeneous HGF treated tumor cell population consisting257
of 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R,T790M, and imposed a constraint that at258
most one switch could occur, as a starting point to simulate what might be most clinically feasible. The259
resulting optimal treatment strategy predicted by our modeling, consisting of the erlotinib/crizotinib (days260
0-5) followed by the afatinib/trametinib (days 5-30) combination, was shown to elicit the best response in261
vitro, validating our predictive model (Fig. 7B).262
To show how a delay in the switching time might aﬀect response to therapy, we tested equivalent initial263
tumor cell populations but changed the treatment strategy to start the afatinib/trametinib combination at264
day 10 instead of at day 5. This resulted in worse overall response than the 5 day switching regimen (Fig.265
7B). The corresponding model simulation highlights that although the erlotinib/crizotinib combination eﬀec-266
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tively targeted the HGF treated EGFRL858R mutation during the first 10 days, it allowed the HGF treated267
EGFRL858R, T790M subclone to dominate for a longer period of time, thereby impeding overall response.268
4 Discussion269
One of the fundamental challenges in the principled design of combination therapies is the pre-existence270
and temporal expansion of intratumor genetic heterogeneity that can often lead to rapid resistance with271
first-line targeted therapies. To address this problem, we sought to develop a new modeling framework to272
systematically design principled tumor monitoring and therapeutic strategies. We applied a receding horizon273
optimal control approach to an evolutionary dynamics and drug response model of lung adenocarcinoma274
that was identified from experimental and clinical data. Based on the clinical and experimental data, our275
computational method generated optimal drug scheduling strategies for a comprehensive set of initial tumor276
cell subpopulation distributions.277
Our initial insight was that constant drug combination strategies that guarantee progression free response278
for tumor cell populations with considerable heterogeneity and/or MET activation, required EGFR TKI279
concentrations that were considerably higher than are typically clinically feasible. At clinically relevant doses,280
these constant combination strategies were not eﬀective against all tumor cell subpopulations and inevitably,281
those subpopulations with even slight evolutionary advantages could undergo clonal expansion and cause282
resistance. To overcome this issue, we used our algorithm to generate optimal drug scheduling strategies that283
could preempt the outgrowth of these subpopulations over fixed switching periods, and showed that these284
strategies outperformed constant combination strategies for most tumor cell subpopulation distributions.285
Notably, our computational analysis showed there was more benefit in applying switching strategies in286
the context of increasing pre-existing genetic heterogeneity and these switching strategies provided more287
robustness guarantees in the presence of perturbations in drug concentrations that can occur in patients. We288
demonstrated successful in vitro validation of our optimal control approach for selected tumor subpopulation289
distributions. In particular, for an in vitro analog of our clinical case, a non-intuitive combination therapy290
switching strategy oﬀered better tumor control than constant treatment strategies.291
We found that the most eﬀective drug scheduling strategies were ones that addressed existing subpopu-292
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lations as they emerged during the course of the treatment, even during a bulk tumor response. In contrast,293
current standard of care clinical practice is generally to delay switching to second-line therapy until after294
there is clear evidence of radiographic or clinical progression. Our approach suggests a paradigm shift that295
would require regular monitoring of an individual patient’s tumor mutational status, for instance by muta-296
tional analysis of plasma cell-free circulating tumor DNA, so-called “liquid biopsies” [32, 33, 34, 35, 36]. Our297
modeling strategy could potentially synthesize this genetic information to yield both the design and priori-298
tization of specific drug regimens and the optimal time for clinical deployment, informed by the molecular299
findings in a particular patient. Such treatments may need to be applied (non-intuitively) during the initial300
tumor response, instead of later during therapy or after drug resistance is readily apparent by standard clini-301
cal measures in some cases. We envision that our approach could help contribute to the shift from a reactive302
to pro-active, dynamic management paradigm in solid tumor patients in the molecular era. Drug scheduling303
strategies synthesized by the algorithm for the initial tumor cell population could be adapted to account for304
genetic alterations that are detected by the analysis of serial liquid (or tumor) biopsies, leading to a dynamic305
learning model through iterative refinements; as such, the model could suggest more eﬀective strategies with306
time. Additional considerations such as pharmacokinetics, the tumor microenvironment and metastatic pro-307
cesses [37, 38] could extend this model to add more clinical relevance. Finally, our approach could guide the308
optimal timing of serial clinical specimen sampling (plasma, tumor) and radiographic analysis to streamline309
clinical management. Overall, the combination of techniques stemming from mathematical optimization and310
control theory combined with more clinically applicable tumor dynamics models is a promising approach311
to aid the rational design, clinical testing, and clinical adoption of dynamic molecular monitoring and drug312
scheduling strategies to better control complex solid cancers such as lung cancer in real-time and improve313
clinical outcomes.314
4.1 Materials and Methods315
4.1.1 Computational Methods316
The details of mathematical models and experimental methods may be found in SI Mathematical Meth-317
ods. The mathematical model of lung adenocarcinoma growth mutation and selection by small molecule318
inhibitors was formulated as system of ordinary diﬀerential equations (ODEs). The treatment strategy algo-319
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rithm was formulated as a receding horizon optimal control problem with the objective of minimizing lung320
adenocarcinoma populations at every horizon and implemented using python version 3.4.3, scipy version321
1.11.0.322
4.1.2 Experimental Methods323
Patient sample preparation and sequence capture. Formalin fixed paraﬃn embedded (FFPE) NSCLC324
fine needle aspirate biopsy specimens and a normal blood sample were obtained from the patient under in-325
stitutional informed consent both prior to erlotinib treatment and upon erlotinib resistance. Lung tumor326
biopsy specimens contained > 75% tumor cells upon histopathological analysis by a board-certified pathol-327
ogist. Barcoded sequence libraries were generated using genomic DNA from FFPE tumor material and328
matched normal blood using the NuGEN Ovation ultralow library systems and according to manufacturer’s329
instructions (NuGEN, San Carlos, CA). These libraries were among an equimolar pool of 16 barcoded li-330
braries generated and subjected to solution-phase hybrid capture with biotinylated oligonucleotides targeting331
the coding exons of 389 cancer-associated genes using Nimblegen SeqV.D.J.Cap EZ (Roche NimbleGen, Inc332
, Madison, WI). Each hybrid capture pool was sequenced in a single lane of Illumina HiSeq2000 instrumen-333
tation producing 100bp paired-end reads (UCSF Next Generation Sequencing Service). Sequencing data was334
demultiplexed to match all high-quality barcoded reads with the corresponding samples.335
336
Sequencing Analysis. Paired-end sequence reads from normal blood, pre-treatment tumor, and erlotinib-337
resistant tumor samples were aligned against build hg19 of the reference genome with BWA [39]. Duplicate338
reads were marked, alignment and hybridization metrics calculated, multiple sequence realignment around339
candidate indels performed, and base quality scores recalibrated across all samples with the Picard suite340
(http://picard.sourceforge.net/) and the Genome Analysis Toolkit (GATK) [40]. Somatic point mutations341
were detected in the treatment-naïve and resistant tumors using MuTect [41], while small insertions and342
deletions (indels) were identified with GATK. Given the depth of sequencing achieved and the presence of343
low-frequency oncogenic mutations in the normal sample likely due to circulating tumor DNA, mutations344
were excluded as germline if they exceeded a frequency of 10% in the normal sample. Non-synonymous muta-345
tions were annotated for their sequence context, eﬀect, and frequency in lung adenocarcinoma and squamous346
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cell tumors from The Cancer Genome Atlas (TCGA) project and Imielinski et al. [42]. All previously347
characterized oncogenic alleles in NSCLC or mutations previously linked to erlotinib resistance were also348
manual inspected in both treatment-naïve and resistant tumors. This analysis revealed a single sequencing349
read bearing the T790M mutation in the primary tumor (total coverage at this locus: 1300x). This was in-350
suﬃcient evidence from sequencing data to formally call the mutation, but we cannot exclude the possibility351
that EGFRT790M exists pre-treatment in a very rare clone (<0.08%) for which our target depth of coverage352
limited our sensitivity. DNA copy number alterations where inferred from the mean sequence coverage for353
each target region in each sample corrected for overall library size. Amplifications and deletions were deter-354
mined from ratios of coverage levels between the pre- and post-treatment tumors and the matched normal355
blood sample. Due to the elevated signal to noise from targeted capture and sequencing of FFPE material356
from lower input amounts, overt genomic amplifications and deletions were required to aﬀect multiple target357
regions (exons) of a given gene before being called as detected. The EGFRT790M and BRAFV600E variants358
were confirmed by a standard Clinical Laboratory Improvement Amendments (CLIA)-approved PCR-based359
shifted termination assay (data not shown). The changes in EGFR and MET copy number were validated360
using established fluorescence in situ hybridization clinical assays.361
362
Cell Lines and Reagents. Human lung cancer cell lines were acquired as previously described [43, 44].363
Cells were grown in RPMI 1640 supplemented with 10% (high serum) or 0.5% (low serum) fetal bovine364
serum (FBS), penicillin G (100U/ml) and streptomycin SO4 (100U/ml). Erlotinib, afatinib, vemurafenib,365
crizotinib, and trametinib were purchased from Selleck Chemicals (Houston, TX). Drugs were resuspended366
in DMSO at a concentration of 10mM and stored at -20  C. Erlotinib and afatinib were used at working367
concentrations ranging from 0.010-1.5 µM. Vemurafenib was used at a working concentration of 5.0 µM, and368
trametinib and crizotinib were used at a 0.5 µM. HGF was purchased from Peprotech (Rocky Hill, NJ) and369
resuspended at 50 g/ml in sterile PBS + 0.1% BSA. Cells were treated with HGF at 50 ng/ml.370
371
Generation of stable cell lines. 293-GPG viral packaging cells were transfected with pBABE (empty372
vector), pBABE-mCherry-BRAF-WT and pBABE-mCherry-BRAFV600E constructs (kindly provided by373
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Dr. Eric Collision, UCSF, San Francisco, CA) using Lipofectamine-2000 (Life Technologies, Pleasanton,374
CA) per manufacturer’s instructions. Virus containing media was harvested three days post transfection375
and used to infect 11-18 and H1975 lung cancer cell lines. Cells were incubated with virus containing media376
supplemented with 6 µg/ml of polybrene for 24 hours. Media was changed to standard cell growth media377
(RPMI-1640 + 10% fetal bovine serum and 100 U/ml penicillin G and 100 U/ml streptomycin SO4) and378
cells were expanded for 48 hours, at which point puromycin (2 µg/ml) was added to the media and cells379
were allowed to grow for an additional 4 days. Cells that survived puromycin selection (stable cell lines)380
were used in all subsequent experiments.381
382
Cell Viability and Growth Assays. Assays were performed as previously described [43, 44]. Briefly, cells383
were seeded overnight at a density of 5,000 cells per well in 96-well plates in RPMI containing 10% FBS and384
treated with indicated reagents for 72 hours. Viable cell numbers were determined using the CellTiterGLO385
assay according to manufacturer’s instructions (Promega). Each assay consisted of six replicate wells and386
was repeated at least twice in independent experiments. Cell viability is presented as the mean (± s.e.m.)387
erlotinib or afatinib inhibitory concentration 50 (IC50). Statistical significance between treatment groups388
was determined by the Bonferroni’s multiple comparisons ANOVA statistical test.389
390
Immunoblot analysis. Cells were harvested 24h after initiation of treatment with reagents. Cells were391
scraped and lysed in lysis buﬀer (50 mM Tris·HCl pH 8.0, 150 mM sodium chloride, 0.1% SDS, 0.5% sodium392
deoxycholate, 1% Triton X 100, 5 mM EDTA containing protease and phosphatase inhibitors (Roche Di-393
agnostics. Indianapolis, IN). After quantitation by Pierce BCA assays (Thermo Scientific, Rockford, IL),394
25 µg of each sample was separated by gel electrophoresis on 4-15% Criterion TGX precast gels (BioRad,395
Hercules, CA) and transferred to nitrocellulose membrane. For immunoblots, the following antibodies were396
used: anti-total EGFR (1:1000 dilution, Bethyl Laboratories, Inc., Montgomery TX), anti-pEGFR, anti-total397
Met, anti-pMet, anti-total Mek, anti-pMek, anti-total Akt, anti-pAkt, anti-total Erk, anti-pErk (1:1000, Cell398
Signaling Technology Inc., Danvers, MA), BRAFV600E Monoclonal Antibody (Clone VE1, 1:1000, Spring Bio-399
science, Pleasonton, CA), BRAF WT (1:1000, Santa Cruz Biotech, Santa Cruz, CA) and anti-actin (1:5000400
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dilution, Sigma-Aldrich, Saint Loius, MO), HRP-conjugated anti-rabbit Ig (used at a 1:3000 dilution, Cell401
Signaling), and HRP-conjugated anti-mouse IgG (used at a 1:3000 dilution, Cell Signaling). Specific proteins402
were detected by using either ECL Prime (Amersham Biosciences, Sunnyvale, CA) or the Odyssey Li-Cor403
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Figure 1: Concurrent genetic alterations drive rapid resistance to EGFR TKI treatment in EGFR-mutant lung
adenocarcinoma. (A) Computed tomography indicates the clinical course and timeline of disease in the patient with
rapid progression on EGFR TKI therapy and shows the EGFR-mutant lung adenocarcinoma (red arrows) analyzed
both prior to erlotinib treatment and upon resistance at 4 months. (B) Key somatic mutations identified by exon-
capture and deep sequencing of the pre- and post-treatment tumor in (A) demonstrating concurrent alterations in
EGFR and BRAF and the frequency of each mutation in pre- and post- treatment tumor samples. P-values indicated
as determined by a two-tailed Fischer’s exact test. (C) DNA copy number alterations inferred from exon-capture and
sequencing data indicate the focal amplification of the EGFRL858R-mutant allele was lost upon acquired resistance
while the patient’s resistant tumor gained a focal amplification of MET, with no change in BRAF (relative positions
indicated, chromosome 7).
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Figure 2: Designing treatment strategies to control tumor cell dynamics. (A) A depiction of the growth, muta-
tion and drug eﬀect model representing the evolutionary dynamics of lung adenocarcinoma in the presence of small
molecule inhibitors, erlotinib (ERL), afatinib (AFA), crizotinib (CRI), trametinib (TRA) and vemurafenib (VEM).
The corresponding ordinary diﬀerential equation model (ODE) is specified in mathematical detail in the Supplemen-
tary Information, Equation (S1). Drug eﬀect curves were determined for 11-18 and H1975 cell lines specified for
both single drugs and combinations of varying concentrations of one EGFR TKI (erlotinib or afatinib), with fixed
concentrations of either 5 µM vemurafenib, 0.5 µM trametinib or 0.5 µM crizotinib (SI, Fig. S1-S4). (B) The design
of constant or switching feedback strategies to control the dynamics of lung adenocarcinoma is approached as an
optimal control problem. The treatment strategy design algorithm (SI, Section 2) solves for feedback strategies that
minimize tumor cell growth over the course of the treatment.
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Figure 3: Mathematical simulation qualitatively captures the patient’s evolution on erlotinib. (A) A simulation of
the mathematical model of lung adenocarcinoma evolution (SI, Equation (S1)) in the presence of 1 µM erlotinib,
given the patient-derived pretreatment initial tumor cell subpopulations (94 % EGFRL858R, 6% BRAFV600E, 0.01%
MET amplification of EGFRL858R, BRAFV600E and EGFRT790M). (B) Tumor cell populations present at day 0, 6
and 17 of the simulation in (A), including the total HGF+ cell population at day 17 (gray). The model qualitatively
captures a possible evolutionary trajectory and results in a similar final tumor cell composition as that of the patient,
(B) day 17 vs. Figure 1, (B) and (C).
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Figure 4: Modeling pharmacodyamic eﬀects of concurrent BRAFV600E expression and MET activation in EGFR-
mutant lung adenocarcinoma cells and their implication on progression. (A) Drug eﬃcacy as measured by the
eﬀect of 1.5 µM erlotinib or 0.5 µM afatinib in combination with either 0.5 µM MET inhibitor crizotinib, 0.5 µM
MEK inhibitor trametinib or 5 µM BRAF inhibitor vemurafenib on cell growth (SI, Equation S1) of parental 11-18
EGFRL858R-positive lung adenocarcinoma cells or those cells engineered to express mutations listed above and treated
with 0 or 50 ng/ml HGF. (B) Concentrations of EGFR TKIs afatinib and erlotinib in combination with either 0.5 µM
crizotinib, 0.5 µM trametinib or 5 µM vemurafenib that guarantee progression free tumor reduction for any HGF- or
HGF+ initial tumor subpopulations according to the model, measured by the minimum concentration of erlotinib or
afatinib that results in exponential stability of the evolutionary dyanmics model (SI, Section 3.2). (C) Simulations of
the lung adenocarcinoma model for combinations of 0.5 µM afatinib+0.5 µM trametinib and 1.5 µM erlotinib+0.5 µM
crizotinib for the HGF- and HGF+ tumors specified. (D) (Left) Simulations of the evolutionary dynamics of diﬀerent
HGF- lung adenocarcinoma initial tumor subpopulations with a constant treatment of 0.7 µM, 0.5, 0.3 or 0.1 µM
afatinib in combination with 0.5 µM of trametinib (red) and of diﬀerent HGF+ lung adenocarcinoma initial tumor
subpopulations with a constant treatment of 8.32 µM, 3.2 µM, 1.5 µM or 0.75 µM erlotinib in combination with 0.5
µM crizotinib (blue). (Right) Maximum eigenvalue decompositions (SI, Section 3.2) classify which subpopulationss
can lead to progression at diﬀerent concentrations of EGFR TKI for the afatinib+trametinib combination and the
erlotinib+crizotinib combination.
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Figure 5: Optimal drug scheduling strategies solved by Algorithm 1 (SI, Section 2.2) for representative initial tumor
cell distributions (A),(C), for a 30 day timeframe and 30, 15, 10, 5, 3 and 1 day minimum switching horizons, give one
EGFR TKI, either 1.5 µM erlotinib (ERL) or 0.5 µM afatinib (AFA) in combination with either 5 µM vemurafenib
(VEM), 0.5 µM trametinib (TRA) or 0.5 µM crizotinib (CRI) and corresponding simulations (B),(D) of the lung
adenocarcinoma evolutionary dynamics for a subset of optimal drug scheduling strategies.
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Figure 6: Exploring the robustness of treatment strategies through model simulation. (A) Switching strategies are
more beneficial to tumor cell populations with more initial heterogeneity. (Left) Fold change in final lung adeno-
carcinoma tumor cell populations at day 30 versus day 0 over the course of the optimal 30, 15, 10, 5, 3, and 1 day
treatment strategies solved by algorithm 1 (SI, Section 2.2) and normalized by fold change in final tumor cell popu-
lation for the constant 30 day treatment strategy for an initial tumor cell population comprised of (90% EGFRL858R,
10% H1975 EGFRL858R,T790M) and another comprised of (89% EGFRL858R, 10% BRAFV600E,1% EGFRL858R,T790M)
subclones. (Right) Sum of fold change for the final lung adenocarcinoma populations (SI, Equation S5) for select
initial tumor cell distributions (SI, Table 1) and their corresponding optimal 30, 15, 10, 5, 3, and 1 day treatment
strategies, categorized by the number of subclones in the initial tumor cell population. Smaller fold change sums
indicate that more switching is beneficial to reduce final populations, whereas larger fold changes indicate that more
switching does not necessarily help in reducing the final tumor populations. (B) EGFR TKI dose perturbations.
(Left) Fold change in number of lung adenocarcinoma cells between day 30 and day 0, as a function of percent
EGFR TKI dose reduction for the optimal 30, 15, 10, 5 and 1 day strategies solved by algorithm 1 (SI, Section 2.2)
for tumor cell populations indicated above. The shaded areas indicate the regions of the perturbation space where
the treatment strategy reduces the initial tumor cell population by more than 30% (response, light blue), increases
the size of the original tumor population size by more than 20% (progression, red), or maintains the original tumor
population size between the two (stability, white). (Right) Bar graphs indicate the maximum reduction in EGFR
TKI dose supported by the optimal strategy such that there is still reduction in tumor size at day 30 with respect
to day 0 for the V600E and the pretreatment MET tumor. (C) The average maximum percent EGFR TKI dose
reduction supported before progression for lung adenocarcinoma tumors with diﬀerent number of initial tumor cell
subpopulations and for predicted optimal 30, 15, 10, 5, and 1 day switching strategies.
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Figure 7: Engineering optimal treatment strategies for concurrent, clonal genetic alterations in EGFR-mutant lung
adenocarcinoma and predicting their therapeutic impact. (A) Simulations of the optimal treatment strategy predicted
by algorithm 1 (SI, Section 2.2) consisting of 1.5 µM erlotinib+0.5 µM crizotinib for days (0-5) followed by 0.5 µM
afatinib+0.5 µM trametinib for days (5-30); the same strategy but with the switch occurring at day 10 and, constant
strategies of 0.5 µM afatinib+0.5 µM trametinib or 1.5 µM erlotinib+0.5 µM crizotinib for 30 days, for an initial
tumor cell population of 89% EGFRL858R, 10% EGFRL858RBRAFV600E, 1% EGFRL858R,T790M, HGF treated. (B)
Evolution experiment shows that the predicted strategy for an initial tumor cell population of 89% EGFRL858R, 10%
EGFRL858RBRAFV600E, 1% EGFRL858R,T790M, treated with 50 ng/ml HGF, is optimal. Overlaid numbers indicate
the relative cell density of each well at day 30 compared to the erlotinib+crizotinib well (magenta). Computational
simulations in (A) show that the predicted optimal strategy has the greatest reduction in tumor cells in vitro (B, red)
compared to the same strategy with a 10 day switch (yellow). A simulation of the model predicts that a constant
treatment of afatinib+trametinib produces little change in number of tumor cells (B, blue) and that a constant
treatment of erlotinib+crizotinib predicts the exponential outgrowth of the initial EGFRL858R,T790M MET amplified
subpopulation, experimentally validated in (B, magenta).
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Supplementary Information
Vanessa D. Jonsson, Collin M. Blakely, et. al.
1 Mathematical Methods
1.1 Evolutionary Dynamics Model of NSCLC
The quasispecies model [1] was originally developed to describe the dynamics of populations of self replicating
macromolecules undergoing mutation and selection. We choose this model for its relative simplicity and its
ability to capture the salient features of the evolutionary dynamics of a simplified generic disease model. The
following adaptation incorporates the eﬀects of small molecule inhibitors and describes the growth, mutation
and evolution of non small cell lung adenocarcinoma populations:
x˙i = riqiixi +
nX
k 6=i
riqikxk   i(`k)xi (S1)
where xi 2 R+ is the concentration of a NSCLC subpopulation i, `k 2 R+ is a small molecule inhibitor
concentration (assumed to remain at constant concentrations throughout), ri is the growth rate for each cell
xi, and qik is the probability that cell k mutates to cell i (note that qii is the probability of no mutation
occurring). Finally, the function  i(`k) represents the pharmacodynamics of individual drugs `k or of
individual EGFR TKIs (erlotinib or afatinib) in combination with fixed concentrations other small molecule
inhibitors used in this study (0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib) with respect to
the i-th NSCLC cell type, namely:






where `k 2 R+ is the drug concentration,  ik 2 R+ is the saturation coeﬃcient, Kik 2 R+ is the dissociation
constant, nk 2 R+ is the Hill coeﬃcient. When `k = 0, 8k 2 {1, ...,m}, the dynamics are unstable.
2 A control theoretic algorithm for designing treatment strategies
To design treatment strategies that best minimize tumor size and control its evolution over time, we combine
both a greedy algorithm and receding horizon control approach. We introduce some notation, cost function
definitions and specify our algorithm.
2.1 Cost functions
To measure the eﬀectiveness of a given treatment strategy over time, we define the average cost function.
For a given treatment strategy `k applied to Equation (S1), we rewrite the dynamics of the entire system
(i.e., for all cells) as
x˙ = A(`k)x, (S3)
where A 2 Rn⇥n is a matrix that represents the growth, mutation and drug dynamics for treatment
strategy `k, for n cell subpopulations.
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The average cost Cr for a time horizon N , allowable switching period ⌧ and time intervals of the form







where 1T is the n⇥ 1-dimensional vector of ones and x(t) is the solution to Equation (S3).




1TA 1(eA`k ((k+1)⌧ k⌧)   I)x(k⌧). (S5)
The final cost Cf for an inital tumor population x(0) and a sequence of drugs {`(k)}N/⌧ 1k=1 that define a




Our algorithm is defined as follows. Given an initial tumor population, denoted by x0, a time horizon N and
an allowable switching period ⌧ , we perform the following computations to determine a candidate treatment
strategy:
Algorithm 1 Treatment strategy synthesis
1. Initialization: Set k = 0 and x(0) = x0.
2. Greedy approach: For time interval [k⌧, (k + 1)⌧ ], compute y((k + 1)⌧) = eA(`k)⌧y(k⌧) for each
possible treatment strategy `k.
3. Update: Set `(k) = argmin`k sum(y(k+1)⌧), and set x((k+1)⌧) = min`k sum(y(k+1)⌧). Increment
k: if k = N , proceed to step 4, otherwise return to step 2.
4. Output: A sequence of drugs {`(k)}N/⌧ 1k=1 that define a switching therapy.
The resulting switching therapy {`(k)} is then applied until the next biopsy can be taken, giving a new
tumor cell population measurement, at which point the algorithm is repeated. In particular, it is important
that the horizon N be chosen to be longer than expected periods between biopsies.
3 Model Implementation and Simulations
3.1 Derivation of dynamical system parameters
Growth and Mutation Rates. We model the growth of NSCLC cell population xi by the following
ordinary diﬀerential equation (ODE):
x˙i = rixi, (S7)
where ri is the growth rate per day, and x˙i denotes the derivative with respect to time of the tumor cell
population xi. Note that we assume that no mutations occur over the time-frame considered, allowing us to
set qii = 1 and qij = 0 in the dynamic model (S1), resulting in (S7).
Given an initial population xi(0), the population xi(t) on day t can be obtained by solving ODE (S7),
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Given a set of N experimental data points ei(0), ei(t1), . . . , ei(tN ), we fit these points to an exponential
function of the form (S8), with xi(0) = ei(0) to obtain an experimentally derived value for the growth rate
ri of tumor cell population xi.
We take the DNA mutation rate to be 1e 9 mutation/base pair/cell division []. We assume that muta-
tions occur unidirectionally from EGFRL858R parental cells to EGFRL858R,T790M, EGFRL858R, BRAFV600E
or EGFRL858R,T790M BRAFV600E, HGF-/+.
Drug Eﬀect Rates and Hill Functions. We model the change in a tumor cell population xi under
a treatment j of concentration ` with the following ordinary diﬀerential equation (ODE):
x˙i = rixi   f ji (`)xi, (S9)
where ri is the growth rate per day derived in the previous section and f ji (`) is a function mapping the
treatment j at concentration ` to a drug eﬀect rate per day. We again assume that no mutation occurs
over the time-frame considered, allowing us to set the mutation rates qii = 1 and qij = 0 in the model (S1),
resulting in (S9).
Similar to the previous section, given an initial population xi(0), the population xi(t) on day t can be
obtained by solving ODE (S9), and is specified by the following expression
xi(t) = xi(0)e
(ri fji (`)t. (S10)
We model the map f ji (`) as a modified function of the form






where  j,i nj,i and Kj,i are the saturation parameter, Hill function coeﬃcient and binding reaction dissoci-
ation constant for drug j applied to cell xi.
Our goal is to obtain values for these three parameters using experimental data measuring cell viability
under varying concentrations ` of drug j. In particular, given experimentally obtained data pairs of the form
`, yi,j,`(1), where yi,j,`(1) is the ratio of the tumor cell population xi treated with concentration ` of drug j
at day 1 to the tumor cell population xi treated with no drug at day 1. Letting x`i denote the treated tumor












where the first equality follows from the definition of yi,j,`(1), the second from applying equations (S10)
and (S8) to x`i(1) and xctrli (1) respectively, and the third from canceling like terms. It follows that the
experimentally derived values of f ji (`) are given by
f ji (`) =   ln(yi,j,`). (S13)
Solving this equation for each experimentally tested concentration `, we obtain a set of points {`, f ji (`)}
that can be used to derive the parameters  j,i nj,i and Kj,i via curve fitting. In order to avoid overfitting,
we set  j,i = max` f ji (`), i.e., we force the modified Hill function to saturate at the maximal experimentally
observed rate. Although this approach can be conservative in modeling the drug eﬀect rate of high concen-
trations of drugs, we note that the the maximal dose tested is chosen to be significantly higher than the
maximum tolerated doses, and hence we do not expect this saturation to aﬀect the accuracy of our model
at clinically relevant doses.
3.2 Evolutionary stability measured by maximum eigenvalues
Figures (S7) and ( main text) depict maximum eigenvalue decompositions of HGF- and HGF+ tumors and
describe the set of initial NSCLC populations, if present can lead to tumor progression upon initiation of
constant (non-switching) combination treatments. For the evolutionary dynamics:
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x˙ = (A D`)x (S14)
where x 2 Rn is a vector of concentrations of n NSCLC subpopulations, x˙ 2 Rn is their rate of change
over time, A 2 Rn⇥n is a matrix that represents the growth and mutation dynamics and D` 2 Rn⇥n is a
diagonal matrix that represents the corresponding drug eﬀect of one constant drug treatment on the rate of
change of NSCLC cells. If all eigenvalues are negative then Equation (S14) is said to be stable. In the case
of NSCLC evolutionary dynamics corresponding to Equation (1), stability refers to tumor reduction, and
instability refers to tumor progression. In section 3.1, we made the assumption that mutation rates are one
directional, hence the A matrix in Equation (1) is lower triangular and the eigenvalues of A D` are exactly
equal to its diagonal entries. For each NSCLC subpopulation, we take the maximum eigenvalue for each
evolutionary branch downstream of the population and define this as evolutionary stability. This maximum
eigenvalue represents the worst case stability if the particular population is present upon treatment initiation
- a positive maximum eigenvalue indicates that the presence of the cell subpopulation in the tumor upon
initiation of treatment is likely to cause therapeutic failure. A negative maximum eigenvalue indicates that
the presence of the particular subpopulation will not outgrow or evolve in the presence of therapy.
3.3 Robustness analysis
Sensitivity to drug perturbations. To analyze the eﬀect of dose reductions on the robustness of constant
and switching treatment strategies, we perturbed the drug concentrations and calculated the ratio of final
cost and initial cost (Figures (S8)) . We rewrite Equation (S1) for one cell xi and one drug `j to illustrate
how a drug perturbation   2 R[0,1] is modeled:
x˙i = riqiixi +
nX
k 6=i






The fold change FCf in total population from day 0 to day N for a sequence of drugs {`(k)}N/⌧ 1k=1










If FCf < 1, the treatment strategy {`(k)}N/⌧ 1k=1 is eﬀective for NSCLC populations for the duration of the
time horizon N , FCf > 1 indicates progression.
3.4 Implementation
The evolutionary dynamics model and simulations were implemented using python, scipy and numpy (ver-
sions 3.5.1, 0.17.0, 1.9.3) and pandas version 0.17.0 was used for data parsing. Data fitting for experimentally
derived cell growth and drug dose response data was performed with Matlab version 8.3.0.532 using the non
linear least squares method.
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Figure S1: Experimentally derived erlotinib, afatinib, vemurafenib, trametinib and crizotinib dose response curves for
11-18 EGFRL858R, 11-18 EGFRL858R BRAFV600E, H1975 EGFRL858R,T790M H1975 EGFRL858R,T790M BRAFV600E
cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with   [`]
n
[`]n+Kn where   is the maximum inhi-
bition, [`] is the EGFR TKI concentration, n is the Hill coeﬃcient and K is the half maximal inhibitory concentration
(IC50).
H1975 EGFRL858R,T790M  
BRAFV600E 11-18 EGFRL858R 
11-18 EGFRL858R HGF+ 
11-18 EGFRL858R BRAFV600E  
11-18 EGFRL858R  
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Figure S2: Experimentally derived dose response curves for erlotinib in combination with 5 µM vemurafenib, 0.5
µM trametinib and 0.5 µM crizotinib for 11-18 EGFRL858R, 11-18 EGFRL858RBRAFV600E, H1975 EGFRL858R,T790M
H1975 EGFRL858R,T790M BRAFV600E cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with
  [`]
n
[`]n+Kn where   is the maximum inhibition, [`] is the EGFR TKI concentration, n is the Hill coeﬃcient and K is
the half maximal inhibitory concentration (IC50).
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11-18 (BRAF wt) 11-18 (BRAF V600E)
Figure S3: Western blot analysis of cell lysates obtained from 11-18 cell line, treated with drugs and/or HGF as
indicated, and probed for the indicated proteins.
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Figure S4: A) Experimentally derived dose response curves for afatinib in combination with 5 µM vemurafenib, 0.5
µM trametinib and 0.5 µM crizotinib for 11-18 EGFRL858R, 11-18 EGFRL858R BRAFV600E, H1975 EGFRL858R,T790M
H1975 EGFRL858R,T790M BRAFV600E cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with
  [`]
n
[`]n+Kn where   is the maximum inhibition, [`] is the EGFR TKI concentration, n is the Hill coeﬃcient and K is
the half maximal inhibitory concentration (IC50). (B) Western blot analysis of cell lysates obtained from H1975 cell
lines, treated with drugs and/or HGF as indicated, and probed for the indicated proteins.
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Figure S5: Simulations of the NSCLC model for constant combinations of 0.5 µM afatinib or 1.5 µM erlotinib with
either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib for a tumor comprised of 89% 11-18 EGFRL858R,
10% 11-18 EGFRL858R, BRAFV600E and 1% H1975 EGFRL858R T790M, and treated with HGF (B) or without HGF
(A).
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Figure S6: Simulations of the NSCLC model for the optimal 30 day constant combinations found by Algorithm (4)
with 0.5 µM afatinib or 1.5 µM erlotinib with either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib for
the relatively low (A) initial tumor heterogeneity or with (B) high initial tumor heterogeneity.
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Figure S7: Classification of initial tumor compositions via eigenvalue decompositions describe the initial tumor
populations that can destabilize of the evolutionary dynamics in the presence of either erlotinib or afatinib and either
0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib.
10
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/086553doi: bioRxiv preprint first posted online Nov. 8, 2016; 







10% BRAFV600E HGF+ 
25% EGFRL858R  
60% BRAFV600E  
15% EGFRT790M HGF+ 
25% EGFRL858R  
60% BRAFV600E  HGF+ 
10% EGFRT790M  
5% BRAFV600E HGF-  






















































25% EGFRL858R  
60% BRAFV600E  
15% EGFRT790M HGF+ 
Figure S8: A) Fold change in NSCLC population at day 30 versus day 0, over the course of the optimal 30, 15, 10,
5, 3, and 1 day treatment strategies solved by algorithm 1 (SI), for indicated tumor compositions, normalized by
fold change in NSCLC population for the constant 30 day treatment strategy (Red). (Blue) Sum of fold change in
the average cost for indicated tumor compositions and corresponding optimal 30, 15, 10, 5, 3, and 1 day treatment
strategies. B) (Above) Fold change in number of NSCLC cells between day 0 and day 30, as a function of percent
EGFR TKI dose reduction for the optimal 30, 15, 10, 5 and 1 day strategies solved by algorithm 1 (SI) for indicated
tumor compositions. Shaded blue areas indicate the region of the perturbation space where the treatment strategy
reduces the size of the initial tumor (stable). The shaded red area indicates the region of the perturbation space
where the treatment strategy increases the size of the original tumor at day 30 (unstable). (Below) The maximum
percent EGFR TKI dose reduction sustainable before the treatment is no longer eﬀective (the tumor progresses).
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Figure S9: The EGFR-mutant lung adenocarcinoma mutation model used in this study.
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Figure S10: Optimal drug scheduling strategies solved by Algorithm 1 (SI, Section 2.2) for representative initial
tumor cell distributions (A),(C), for a 30 day timeframe and 30, 15, 10, 5, 3 and 1 day minimum switching horizons,
give one EGFR TKI, either 1.5 µM erlotinib (ERL) or 0.5 µM afatinib (AFA) in combination with either 5 µM
vemurafenib (VEM), 0.5 µM trametinib (TRA) or 0.5 µM crizotinib (CRI) and corresponding simulations (B),(D) of
the lung adenocarcinoma evolutionary dynamics for a subset of optimal drug scheduling strategies.
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11-18 EGFRL858R 0.58 
11-18 EGFRL858R HGF+ 0.67 
11-18 EGFRL858R BRAFV600E  0.60 
11-18 EGFRL858R BRAFV600E HGF+ 0.70 
H1975 EGFRL858R,T790M 0.63 
H1975 EGFRL858R,T790M BRAFV600E  0.59 
H1975 EGFRL858R,T790M HGF+ 0.77 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 0.64 
Table 1: Experimentally derived growth rates in parental and engineered 11-18 EGFRL858R-positive lung adenocar-
cinoma cells and treated with or without HGF, fit with Equation (S8).
IC50 in µM 
Cellname Erlotinib Afatinib Crizotinib Trametinib Vemurafenib 
11-18 EGFRL858R 0.19 0.20 2.72 12.69 16.38 
11-18 EGFRL858R HGF+ 7.93 1.33 6.81 1.59 50.18 
11-18 EGFRL858R BRAFV600E  0.91 0.49 3.25 15.59 10.60 
11-18 EGFRL858R BRAFV600E HGF+ 8.74 1.49 10.54 1.49 12.64 
H1975 EGFRL858R,T790M 7.54 0.08 9.33 0.76 48.31 
H1975 EGFRL858R,T790M BRAFV600E  9.32 0.18 8.18 0.82 18.64 
H1975 EGFRL858R,T790M HGF+ 7.04 0.60 25.59 0.12 53.89 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 7.97 0.82 31.83 0.06 54.48 
Table 2: Drug sensitivity as measured by the IC50 of erlotinib, afatinib, vemurafenib, trametinib and crizotinib in
parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma cells.
IC50 Erlotinib in µM 
Cell name  +0.5 µM Crizotinib  +0.5 µM Trametinib  +5 µM Vemurafenib 
11-18 EGFRL858R 0.30 0.19 0.30 
11-18 EGFRL858R HGF+ 0.18 0.47 1.34 
11-18 EGFRL858R BRAFV600E  1.64 0.08 0.09 
11-18 EGFRL858R BRAFV600E HGF+ 3.58 7.95 0.86 
H1975 EGFRL858R,T790M 3.51 7.83 15.39 
H1975 EGFRL858R,T790M BRAFV600E  3.71 7.68 9.86 
H1975 EGFRL858R,T790M HGF+ 7.78 8.20 31.01 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 6.70 5.50 103.67 
Table 3: Drug sensitivity as measured by the IC50 of erlotinib in combination with 5 µM vemurafenib, 0.5 µM
trametinib and 0.5 µM crizotinib in parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma cells.
IC50 Afatinib in µM 
Cell name  +0.5 µM Crizotinib  +0.5 µM Trametinib  +5 µM Vemurafenib 
11-18 EGFRL858R 0.42 0.17 0.11 
11-18 EGFRL858R HGF+ 1.96 0.79 1.27 
11-18 EGFRL858R BRAFV600E  1.10 0.32 0.37 
11-18 EGFRL858R BRAFV600E HGF+ 2.60 0.48 2.54 
H1975 EGFRL858R,T790M 0.06 0.01 0.04 
H1975 EGFRL858R,T790M BRAFV600E  0.07 0.03 0.04 
H1975 EGFRL858R,T790M HGF+ 0.19 0.00 0.11 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 0.41 0.00 0.61 
Table 4: Drug sensitivity as measured by the IC50 of afatinib in combination with 5 µM vemurafenib, 0.5 µM
trametinib and 0.5 µM crizotinib in parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma cells.
14
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/086553doi: bioRxiv preprint first posted online Nov. 8, 2016; 
Erlotinib Afatinib 
Cell name γ n K γ n K 
11-18 EGFRL858R 2.59 0.54 1.22 73.45 0.32 424540.00 
11-18 EGFRL858R HGF+ 0.61 3.81 7.93 1885.80 0.70 106610.00 
11-18 EGFRL858R BRAFV600E  1.72 0.53 1.90 297.20 0.46 269500.00 
11-18 EGFRL858R BRAFV600E HGF+ 0.39 3.48 8.74 590.76 0.72 18112.00 
H1975 EGFRL858R,T790M 1.87 2.23 9.54 3.77 1.49 0.22 
H1975 EGFRL858R,T790M BRAFV600E  1.50 3.86 9.70 5.14 0.62 3.67 
H1975 EGFRL858R,T790M HGF+ 0.52 3.67 7.04 250.96 0.56 21189.00 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 0.31 3.50 7.97 5.14 1.26 3.57 
Table 5: Diﬀerential equation parameters derived using Equation (S11), corresponding to experimentally derived dose
response curves of erlotinib and afatinib for parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma
cells.
Crizotinib Trametinib Vemurafenib 
Cell name γ n K gamma n K γ n K 
11-18 EGFRL858R 8.80 1.84 10.36 207.05 0.94 5504.20 825.97 0.95 27377.00 
11-18 EGFRL858R HGF+ 6.14 3.89 11.57 3.47 1.29 4.67 9.81 4.42 89.86 
11-18 EGFRL858R BRAFV600E  74.60 1.59 61.34 1135.50 0.88 67225.00 672.41 0.69 236280.00 
11-18 EGFRL858R BRAFV600E HGF+ 235.65 0.57 270080.00 3.51 1.36 4.17 229.34 0.64 104240.00 
H1975 EGFRL858R,T790M 6.98 1.68 34.62 28.40 0.26 1064100.00 1.56 5.88 50.20 
H1975 EGFRL858R,T790M BRAFV600E  6.52 1.99 23.88 35.42 0.28 1223700.00 6.92 2.35 47.51 
H1975 EGFRL858R,T790M HGF+ 4.66 2.51 51.31 47.17 0.27 900880.00 9.35 4.95 89.74 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 1.69 2.79 36.20 38.13 0.25 595280.00 8.62 4.92 89.37 
Table 6: Diﬀerential equation parameters derived using Equation (S11), corresponding to experimentally derived dose
response curves of crizotinib, trametinib and vemurafenib for parental and engineered 11-18 EGFRL858R-positive lung
adenocarcinoma cells.
Erlotinib+0.5 µM Crizotinib Erlotinib+0.5 µM Trametinib Erlotinib+5 µM Vemurafenib 
Cell name γ n K γ n K γ n K 
11-18 EGFRL858R 49.60 0.32 215970.00 23.91 0.38 2057.10 1.87 0.45 0.96 
11-18 EGFRL858R HGF+ 13.87 0.31 2167.30 197.39 0.44 180410.00 4.03 0.44 46.41 
11-18 EGFRL858R BRAFV600E  5.02 0.38 204.43 3.10 0.77 0.41 1.11 0.85 0.05 
11-18 EGFRL858R BRAFV600E HGF+ 3.79 0.75 26.45 1.28 0.95 6.69 1.97 0.95 1.63 
H1975 EGFRL858R,T790M 990.17 0.74 65062.00 6.43 0.80 110.13 3.01 0.97 53.62 
H1975 EGFRL858R,T790M BRAFV600E  3.40 1.22 11.30 2.29 4.29 9.33 2.20 1.54 16.34 
H1975 EGFRL858R,T790M HGF+ 3.37 2.08 14.90 2.34 4.05 10.15 1.07 2.12 23.25 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 3.65 1.22 21.97 2.06 1.76 8.08 3.04 1.27 271.56 
Table 7: Diﬀerential equation parameters as derived using Equation (S11), corresponding to experimentally derived
dose response curves of erlotinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib
for parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma cells.
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Afatinib+0.5 µM Crizotinib Afatinib+0.5 µM Trametinib Afatinib+5 µM Vemurafenib 
Cell name γ n K γ n K γ n K 
11-18 EGFRL858R 102.02 0.36 363520.00 190.37 0.42 116910.00 41.09 0.27 314410.00 
11-18 EGFRL858R HGF+ 212.01 0.49 209360.00 42.67 0.29 977910.00 66.90 0.36 344940.00 
11-18 EGFRL858R BRAFV600E  310.67 0.52 132530.00 141.93 0.60 2315.40 101.84 0.35 673450.00 
11-18 EGFRL858R BRAFV600E HGF+ 1440.80 0.69 161180.00 54.46 0.31 621930.00 311.18 0.61 57467.00 
H1975 EGFRL858R,T790M 3.75 1.25 0.19 19.69 0.18 572790.00 3.87 0.77 0.26 
H1975 EGFRL858R,T790M BRAFV600E  3.68 1.44 0.18 26.30 0.22 451080.00 3.70 1.07 0.17 
H1975 EGFRL858R,T790M HGF+ 1549.80 0.77 4033.50 14.89 0.24 285.48 110.87 0.36 171470.00 
H1975 EGFRL858R,T790M BRAFV600E HGF+ 4.59 1.88 1.02 35.76 0.23 34108.00 411.18 0.52 140300.00 
Table 8: Diﬀerential equation parameters derived using Equation (S11), corresponding to experimentally derived dose
response curves of afatinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib for
parental and engineered 11-18 EGFRL858R-positive lung adenocarcinoma cells.
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